Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on LinkedIn:
“Following the presentation of the landmark DeLLphi-304 trial on Tarlatamab vs SoC Chemotherapy in pts with pre-treated SCLC in ASCO25, join Dr Jacob Sands and me on June 17th in a hands-on, comprehensive read-out discussion on DLL-3 T-cell engagers and SCLC hosted by only Peters Solange.
Link to Registration.”
Giannis Mountzios announced his upcoming participation in a post-ASCO25 discussion on the DeLLphi-304 trial and the role of DLL3 T-cell engagers in small cell lung cancer. The session will take place on June 17 and be hosted by Peters Solange, with Dr. Jacob Sands also contributing.
More posts featuring Giannis Mountzios.